Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Oppenheimer analyst Leland Gershell maintains Lumos Pharma (NASDAQ:LUMO) with a Outperform and lowers the price target from ...
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.24) ...
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.18...
HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.
Oppenheimer analyst Leland Gershell maintains Lumos Pharma (NASDAQ:LUMO) with a Outperform and maintains $16 price target.
